Overview
ERS Genomics licenses foundational CRISPR/Cas9 intellectual property from Nobel Laureates Emmanuelle Charpentier and Jennifer Doudna, covering over 85 patents worldwide. The company provides non-exclusive licenses for research and commercial applications outside direct human gene and cell therapy, supporting biotech, pharma, agriculture, and synthetic biology. It offers an Express License platform for fast, affordable access tailored to startups and small research enterprises.
Frequently asked questions
- What CRISPR/Cas9 licensing options does ERS Genomics provide?
- ERS Genomics offers non-exclusive licenses for internal research and commercial uses outside direct human therapeutics, including an Express License platform for quick access via online application for eligible startups and small enterprises.
- Which industries and applications are covered by ERS Genomics licenses?
- Licenses support biotech, pharma, agriculture, synthetic biology, preclinical model development, base editing, prime editing, and CRISPR-based gene regulation for freedom-to-operate under foundational patents.
- How can companies obtain a CRISPR/Cas9 license from ERS Genomics?
- Companies negotiate licenses for research and commercial use or apply for Express Licenses online by demonstrating eligibility through publications, collaborations, or patents; ERS focuses solely on IP licensing, not technology provision.